SpliceBio raises €50M Series A round co-lead by UCB Ventures and Ysios, and also backed by New Enterprise, Gilde, NovartisVF and Asabys

16/02/2022 Nota de prensa SPLICEBIO RAISES €50M IN OVERSUBSCRIBED SERIES A FINANCING TO ADVANCE PROTEIN SPLICING PLATFORM AND EXPAND GENE THERAPY PIPELINE.         • Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners • Unique Protein Splicing platform enables…